Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $59.89M rose 79.1% year over year, ahead of the +23.4% change in trailing-twelve-month research & development. Sequentially, it rose 9.9% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.
Context
- Research & development amounted to 1148.2% of revenue in FY2025.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +79.1% holds above the trailing-twelve-month pace of +23.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 172.22M USD
- Year-over-year change
- +14.6%
- 4-year CAGR
- +15.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 172.22M | +14.6% |
| FY2024 | 2024-12-31 | 150.24M | +20.8% |
| FY2023 | 2023-12-31 | 124.41M | -19.8% |
| FY2022 | 2022-12-31 | 155.08M | +61.0% |
| FY2021 | 2021-12-31 | 96.32M | — |
Research & Development vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.4% is the 3rd highest of 10, against a peer median of +14.4%.
- Over three fiscal years its annual growth of +3.6% compares with a peer median of +40.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.08B CNY | +14.4% | +13.4% | 194.0% |
| LTM Mar 2026 | $770.95M USD | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $445.71M USD | +17.2% | +40.8% | — | |
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Sep 2026 | $371.08M USD | +36.1% | +41.7% | — | |
| LTM Jun 2026 | $240.74M USD | +15.7% | +97.7% | — | |
| LTM Jun 2026 | $236.92M USD | +3.2% | -8.3% | 52.7% | |
| LTM Mar 2026 | $198.67M USD | +23.4% | +3.6% | — | |
| LTM Sep 2026 | $167.57M USD | +47.7% | +59.0% | 2717.6% | |
| LTM Jun 2026 | $136.69M USD | +2.4% | +60.2% | — | |
| Peer median (excluding CNTA) | — | +14.4% | +40.8% | 115.2% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6.85M | 0 | 15M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 6.85M | 0 | 15M |
| Gross Margin | — | — | 100.0% | — | 100.0% |
| Research & Development | 96.32M | 155.08M | 124.41M | 150.24M | 172.22M |
| Selling, General & Admin | 43.01M | 55.2M | 53.73M | 50.81M | 50.47M |
| Operating Expenses | 374.87M | 212.26M | 178.14M | 201.06M | 222.69M |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| EBITDA | (139.3M) | (209.55M) | (165.43M) | (221.88M) | (183.33M) |
| EBITDA Margin | — | — | -2413.9% | — | -1222.2% |
| Operating Income | (374.87M) | (212.26M) | (171.28M) | (201.06M) | (207.69M) |
| Operating Margin | — | — | -2499.4% | — | -1384.6% |
| Interest Income | 0 | 244K | 10.48M | 14.02M | 20.53M |
| Interest Expense | 2.55M | 7.28M | 9.91M | 10.09M | 11.46M |
| Other Income / Expenses | (6.92M) | (4.69M) | (4.86M) | (31.86M) | 11.98M |
| Income Before Tax | (381.79M) | (216.95M) | (176.14M) | (232.91M) | (195.71M) |
| Pre-Tax Margin | — | — | -2570.3% | — | -1304.8% |
| Income Tax Expense | 114K | (747K) | (25.06M) | 2.84M | 1.82M |
| Net Income | (381.9M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Net Margin | — | — | -2204.7% | — | -1316.9% |
| EPS (Basic) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| EPS (Diluted) | (4.24) | (2.31) | (1.57) | (2.06) | (1.46) |
| Weighted Avg Shares | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
| Weighted Avg Shares (Diluted) | 89.99M | 93.4M | 96.18M | 114.47M | 135.72M |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.